Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008

(2016) Chezi Ganzel et al.   JOURNAL OF CLINICAL ONCOLOGY

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

(2016) I. A. Asangani et al.   MOLECULAR CANCER RESEARCH

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

(2016) H. K. Bid et al.   MOLECULAR CANCER THERAPEUTICS

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

(2016) Marc Hafner et al.   NATURE METHODS

Functional interdependence of BRD4 and DOT1L in MLL leukemia

(2016) Omer Gilan et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Managing risks in drug discovery: reproducibility of published findings

(2016) Aimo Kannt et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer

(2016) L L da Motta et al.   ONCOGENE

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

(2016) A. Stathis et al.   Cancer Discovery

Functional interdependence of BRD4 and DOT1L in MLL leukemia

(2016) Omer Gilan et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

BET inhibition as a new strategy for the treatment of gastric cancer

(2016) Raquel C. Montenegro et al.   Oncotarget

Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function

(2016) Andre Kleensang et al.   Scientific Reports

Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains

(2016) Akifumi Nakagawa et al.   Scientific Reports

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1

(2016) Zhenfeng Zhang et al.   Theranostics

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer

(2016) Alison M. Kurimchak et al.   Cell Reports

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

(2015) Philipp Rathert et al.   NATURE

BET inhibitor resistance emerges from leukaemia stem cells

(2015) Chun Yew Fong et al.   NATURE

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia

(2015) E Saland et al.   Blood Cancer Journal

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition

(2015) Weilong Yao et al.   Oncotarget

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

(2015) Marie-Magdelaine Coudé et al.   Oncotarget

SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML

(2015) Shuang Ma et al.   Scientific Reports

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1

(2015) Krishan Kumar et al.   Scientific Reports

Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia

(2015) Juan José Fung et al.   eLife

Conducting Meta-Analyses inRwith themetaforPackage

(2015) Wolfgang Viechtbauer   Journal of Statistical Software

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

(2015) Harald Herrmann et al.   Oncotarget

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

(2014) W. Fiskus et al.   MOLECULAR CANCER THERAPEUTICS

Standardised animal models of host microbial mutualism

(2014) A J Macpherson et al.   Mucosal Immunology

Policy: NIH to balance sex in cell and animal studies

(2014) Janine A. Clayton et al.   NATURE

An open investigation of the reproducibility of cancer biology research

(2014) Timothy M Errington et al.   eLife

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition

(2013) C. Chen et al.   GENES & DEVELOPMENT

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

(2013) M A Dawson et al.   LEUKEMIA

Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature

(2013) K. M. Kokolus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FlowRepository: A resource of annotated flow cytometry datasets associated with peer-reviewed publications

(2012) Josef Spidlen et al.   CYTOMETRY PART A

MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome

(2011) Q.-f. Wang et al.   BLOOD

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Guidelines for accurate EC50/IC50 estimation

(2010) J. L. Sebaugh   PHARMACEUTICAL STATISTICS

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

(2009) M. A. Hardwicke et al.   MOLECULAR CANCER THERAPEUTICS

Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation

(2008) Blaine W. Robinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

The effect of cantharidins on leukemic stem cells

(2008) David C. Dorn et al.   INTERNATIONAL JOURNAL OF CANCER